MDXG Q4 2021 Earnings — MiMedx Group, Inc. Revenue & Financial Results | Market Cap Arena

MDXGMiMedx Group, Inc.

$684M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$67M-1.7% YoY

Gross Profit

$57M84.0% margin

Operating Income

$3M4.9% margin

Net Income

$2M3.3% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$188M

Total Liabilities

$95M

Stockholders' Equity

$93M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$69M	-1.7%
Gross Profit	$57M	$58M	-1.9%
Operating Income	$3M	-$16M	+120.5%
Net Income	$2M	-$17M	+113.4%

Revenue Segments

Health Care

$67M50%

Advanced Wound Care, Tissue And Other

$60M45%

Advanced Wound Care, Umbilical Cord-Derived

$7M5%

Section 351

$400,0000%

Product and Service, Other

$74,0000%